Addiction

Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Opioid-free and addiction-free pain treatment therapy could address $1.5B worldwide CINP marketATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics,...

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

NYC Building & Construction Industry Safety Fund program will equip local workers, contractors and staff with NARCAN® Nasal Spray and...

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM...

Drs. Jeffrey Lieberman, M.D. and David Sinclair, Ph.D. to Present ‘The New Frontier of Longevity Science: Living Well Beyond Your Years’ at SXSW 2025

World-leading authorities explore the potential for extending human lifespan on Monday, March 10 at the JW Marriott AustinAUSTIN, Texas, March 07,...

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025

SEATTLE and VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty...

Bicycle Health & Wellpath Sign Additional 1-Year Contract with Federal Bureau of Prisons (FBOP) to Continue Opioid Use Disorder Treatment for Patients in Community Placements

This telehealth-based treatment program started in 2023 and has treated over 2600 patients, allowing them to continue treatment after release,...

error: Content is protected !!